Tibotec’s long-awaited, well-studied protease inhibitor (PI) TMC114
will be in expanded access this fall (www.tibotec.com will have details
soon). The PI boasts a resistance pattern all its own, holding
hope for those who’ve run out of PIs. Boosted with Norvir and
paired with a med to which you’re not resistant—like entry inhibitor
Fuzeon—it promises to lower rising viral loads. Expect FDA approval of
114 in ’06.